Assembly Biosciences is attempting the tricky feat of repurposing a single drug candidate for multiple liver diseases, and a freshly filled $100 million war chest suggests investors are willing to back the strategy. The biotech closed a public offering of 3.36 million shares at $26.50 apiece on Tuesday, with Gilead Sciences, Commodore Capital, Farallon Capital Management and other healthcare-focused funds leading the charge. Despite the 27% dilution, the stock climbed 6.94% on Friday to $28.34 — a vote of confidence that the cash will buy enough runway to deliver pivotal data.
The capital injection roughly doubles the company’s cash position, which stood at $226.6 million at the end of the first quarter. Assembly now expects to remain funded through the end of 2028, a stretch that covers both the mid-stage expansion of its lead asset ABI‑6250 and the looming decision on a cost-sharing deal with Gilead for two herpesvirus candidates.
From Hepatitis Delta to a Broader Liver Play
ABI‑6250, an oral inhibitor of the NTCP membrane protein, is the only clinical‑stage entry blocker for chronic hepatitis D virus infections — a rare and aggressive form of viral hepatitis. But Assembly is widening its sights. Having completed chronic toxicology studies and a Phase 1a trial, the company plans to launch a Phase 2 study for HDV in the fourth quarter of 2026, followed by a basket trial in primary biliary cholangitis and primary sclerosing cholangitis during the first quarter of 2027. A pre‑IND dialogue with the FDA on the cholestasis indications was constructive, though official meeting minutes are still pending.
The scientific foundation for that expansion will come into sharp focus this week. On Wednesday, May 27, Edward J. Gane of the University of Auckland will present Phase 1a safety, pharmacokinetic and pharmacodynamic data for ABI‑6250 at the EASL Congress in Barcelona. The poster, titled “Safety, Pharmacokinetics, and Pharmacodynamic Activity of ABI‑6250 … in Healthy Subjects,” will appear in the session on novel hepatitis B and D therapies. Early results already showed dose‑dependent increases in plasma bile acids — a biomarker confirming NTCP blockade.
Should investors sell immediately? Or is it worth buying Assembly Biosciences?
A Tight Calendar of Catalysts
The EASL presentation marks the first public readout for ABI‑6250 and will serve as an early test of its viability as a multi‑indication asset. If the safety and PD profile hold, the path into Phase 2 for both HDV and cholestatic disease becomes clearer. The timing is crucial: the stock has slid more than 16% year‑to‑date and sits 26% below its 52‑week high of $38.50. The relative strength index of 28.6 points to oversold conditions, leaving the shares highly sensitive to the data.
A second catalyst looms by mid‑2026. Assembly must decide by then whether to exercise its option to enter a U.S. co‑development agreement with Gilead for the herpes simplex virus candidates ABI‑5366 and ABI‑1179, which would carry a 40% cost and profit split. The company already presented Phase 1b data for those programs. Meanwhile, Gilead’s recent decision not to exercise its option on the hepatitis B candidate ABI‑4334 has returned full rights to Assembly, which is now hunting for a new partner.
For a biotech with a market cap that has more than doubled over the past 12 months but remains volatile, the next few weeks will determine whether the pipeline story can drive sustained momentum — or whether this week’s data will prove to be just another short‑lived spark.
Ad
Assembly Biosciences Stock: Buy or Sell?! New Assembly Biosciences Analysis from May 24 delivers the answer:
The latest Assembly Biosciences figures speak for themselves: Urgent action needed for Assembly Biosciences investors. Is it worth buying or should you sell? Find out what to do now in the current free analysis from May 24.
Assembly Biosciences: Buy or sell? Read more here...
